Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer

PURPOSE: An oxaliplatin-based regimen is the most common adjuvant chemotherapy for patients with stage II/III colorectal cancer, but many patients experience dose reduction or early termination of chemotherapy due to side effects. We conducted this study to verify the range of reduction with oncolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Dawon, Baek, Se-Jin, Kwak, Jung-Myun, Kim, Jin, Kim, Seon-Hahn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Surgical Society 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880977/
https://www.ncbi.nlm.nih.gov/pubmed/29629354
http://dx.doi.org/10.4174/astr.2018.94.4.196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880977/
https://www.ncbi.nlm.nih.gov/pubmed/29629354
http://dx.doi.org/10.4174/astr.2018.94.4.196

Ejemplares similares